Search

Author/Creator Merker, Ludwig

1. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Issue 1 (October 2015)

Authors:
Haering, Hans-Ulrich; Merker, Ludwig; Christiansen, Anita Vedel; Roux, Flavien; Salsali, Afshin; Kim, Gabriel; Meinicke, Thomas; Woerle, Hans J.; Broedl, Uli C.; on behalf of the EMPA-REG EXTEND™ METSU investigators
Journal:
Diabetes research and clinical practice
Issue:
Volume 110:Issue 1(2015)
Page Start:
82
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Issue 1 (December 2015)

Authors:
Roden, Michael; Merker, Ludwig; Christiansen, Anita; Roux, Flavien; Salsali, Afshin; Kim, Gabriel; Stella, Peter; Woerle, Hans; Broedl, Uli
Journal:
Cardiovascular diabetology
Issue:
Volume 14:Issue 1(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow‐up registry. Issue 3 (20th December 2022)

Authors:
Kress, Stephan; Bramlage, Peter; Holl, Reinhard W.; Möller, Christian Dominik; Mühldorfer, Steffen; Reindel, Jörg; Seufert, Jochen; Landgraf, Rüdiger; Merker, Ludwig; Meyhöfer, Sebastian M.; Danne, Thomas; Fasching, Peter; Mertens, Peter R.; Wanner, Christoph; Lanzinger, Stefanie
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 25:Issue 3(2023)
Page Start:
776
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗